| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.27B | +59.4% |
| Gross profit | ¥0.06B | — |
| Operating income | ¥0.02B | — |
| Net income | ¥0.02B | — |
| Gross margin | 20.6% | Net margin 7.6% |
| Revenue Q/Q | +3.1% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.21B | 79.4% |
| R&D | ¥0.02B | 8.5% |
| SG&A | ¥0.01B | 4.9% |
| Tax & other | ¥0.00B | 1.5% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
国科微 ・ 佩蒂股份 ・ 宇信科技 ・ 建科院 ・ 华大基因 ・ 英科医疗 ・ 中科信息 ・ 电连技术 ・ 隆盛科技 ・ 英搏尔 ・ 朗新科技 ・ 海特生物
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies